RUNX1 and intrahepatic cholangiocarcinoma: Based on ICC, excluding RUNX1 mutations and SF3B1 VAFs <10% from the MDS-SF3B1 entity, a similar significant separation regarding OS was achieved between ICC MDS-SF3B1 cases and non-MDS-SF3B1 cases represented by MDS, NOS (p = 0.005; Supplementary Fig. S4H).